Lex Machina Antitrust Litigation Report Shows Decline in New Case Filings and Strong Influence of Multidistrict Litigation
This post has been viewed 3,013 times.
Cases against pharmaceutical and chemical companies dominated new case filings
The federal government was the top plaintiff and pork manufacturers were the top defendant in non-multidistrict litigation cases
Federal courts awarded over $4.3 billion total damages in antitrust cases in 2018
Lex Machina, a LexisNexis company and creator of the award-winning Legal Analytics® platform, today released findings from its second Antitrust Litigation Report, which illuminates trends and insights from more than 9,000 antitrust cases active since 2009, including Sherman Act, Clayton Act and Federal Trade Commission Act violations, as well as analysis of multidistrict litigation (MDL). To request a full copy of the report, please visit pages.lexmachina.com/Email_Antitrust-Report-2019_LP-Email.html.
The report found that new antitrust case filings in 2018 were the lowest since 2011 (548 cases) after peaking in 2015 (922 cases). The majority of parties involved in antitrust litigation between 2016 and 2018 were generic drug manufacturers and pharmacies. However, when MDL-associated cases were removed, the federal government was the top plaintiff and pork products manufacturers were the top defendants.
Read original articleTags:
